DICE Therapeutics
define the optimal inhibitory profile | DICE Therapeutics
Company
Deck Type
Deck date
March 2023
Slide
23 of 59
Related slides by other companies
BioNTech
Results
November 2020
phase a safety profile | BioNTech
Matinas BioPharma
Investor Presentation
August 2023
enact cohort results validation of efficacy and safety | Matinas BioPharma
Nuvalent
Investor Presentation
May 2023
preliminary safety profile favorable and consistent with the highly selective sparing design of | Nuvalent
Matinas BioPharma
Investor Presentation
January 2024
enact phase clinical validation of safety and efficacy | Matinas BioPharma
Other recent decks by DICE Therapeutics
See all presentations (4 decks)
Results
March 2023
Investor Presentation
March 2023
Results
October 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io